Abstract:Abstract Objective: DNA amplifications of the cMET locus (METamp) are rare (1-6%) in non-small cell lung cancer (NSCLC). The ability to efficiently identify patients with METamp could accelerate development of cMET-targeting therapies by identifying patients for enrollment efficiently. We developed a self-supervised deep learning algorithm (SSDL) to predict METamp status using H&E stained whole slide images (WSI). Methods: Three datasets (CDtrain, CDNGS, CDFISH) consisting of data from 1,436 advanced NSCLC patients (1 slide/pt) were used to develop an SSDL algorithm to predict METamp status. The METamp+ status across datasets was standardized for CDtrain (n=788, METamp+ Prevalence=15%), CDNGS (n=186, 19 positive, 167 negative, Prev=10%) as harboring ≥5 copies of the gene using NGS(Next Generation Sequencing) and for CDFISH (n=462, 36 positive, 426 negative, Prev=8%) as MET CN gain to centromere 7 ratio (CEN) ≥2.5. The datasets were divided into a discovery set (CDtrain) for training and held-out test sets (CDNGS, CDFISH) for validation. To improve robustness of SSDL, we first pre-trained ResNet34 with Simple Contrastive Learning, using >25k WSIs from diverse sources. During the training phase, 4-fold cross validation was applied on CDtrain. The first 3-layers of ResNet34 were frozen while the final layer and an attention-based aggregation system were trained for METamp prediction. The performance was assessed using sensitivity, specificity, AUC, positive predictive value (PPV), and negative predictive value (NPV) on the test sets. Predictions from the model were binarized using two separate thresholds selected from CDtrain, resulting in a High-Sensitivity model (SSDLSens = 90% Sensitivity) and High-Specificity model (SSDLSpec = 90% Specificity). Each model’s potential impact on patient enrollment is presented below. Results: The trained SSDL models achieved an average cross-validation AUC of 0.77±0.04 across folds. The final trained model with the highest cross-validated AUC was chosen for METamp status prediction on the test sets. The selected model maintained predictive performance on CDNGS (AUC=0.82) and CDFISH (AUC=0.75) test sets. The SSDLSpec model had a PPV more than twice the baseline prevalence in both CDNGS (PPV=27%), and CDFISH (PPV=29%), providing a significant enrichment in METamp+ patients. The SSDLSens model correctly classified ~55% of METamp‒ in CDNGS and CDFISH with NPV of ≥97%. These results suggest a potential reduction in genetic screening by 50% while maintaining high sensitivity. Conclusions: The SSDL model robustly predicted METamp status in independent patient cohorts, regardless of METamp definitions (i.e., by NGS or FISH). We demonstrate the ability to classify patients with high sensitivity or specificity, which can help reduce genetic testing or surface potentially eligible patients for trials, respectively. Citation Format: Chaitanya Parmar, Oscar M. Carrasco-Zevallos, Joshua C. Curtin, Darshana Govind, Bing Xia, S. Martin Shreeve, Songbai Wang, Timothy Jatkoe, Patricia Raciti, Levon Demirdjian, Joel Greshock, Kristopher Standish, Stephen S.F. Yip. Prediction of MET amplification from H&E images in non small cell lung cancer using self-supervised deep learning and its role in clinical trial enrollment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6554.

Abstract 5440: Deep-learning model for tumor type classification enables enhanced clinical decision support in cancer diagnosis

Deep Learning Model for Tumor Type Prediction using Targeted Clinical Genomic Sequencing Data

Abstract 5045: Genomics and pathology based deep learning to predict cancers of unknown primary

Abstract 6371: Deep learning algorithm for multi-cancer detection and classification using cf-WGS

Abstract 4951: Integrative multi-omic machine learning model predicts neoadjuvant immunotherapy response using molecular data and deep learning-derived features from digital pathology

Abstract 6554: Prediction of MET amplification from H&E images in non small cell lung cancer using self-supervised deep learning and its role in clinical trial enrollment

Abstract 910: Clinical inference and biological dissection of tumor ploidy and heterogeneity in cutaneous melanoma for immunotherapy response using deep learning

Abstract 4939: Computational pathology approach for prognostic advancements and therapeutic benefits in gastrointestinal cancer: A multi-centric retrospective study

Abstract 886: Integrated deep learning model for predicting DNA methylation and tumor types from histopathology in central nervous system tumors

Abstract 4970: Multi-modal machine learning approaches for predicting cancer type and Gleason grade leveraging public TCGA data

DeepGene: an Advanced Cancer Type Classifier Based on Deep Learning and Somatic Point Mutations

A Deep Learning Model for Cancer Type Prediction Sets a New Standard

Abstract 889: Machine learning-enhanced targeted versus whole-exome sequencing as a guide to cancer care

Abstract 4298: Predicting tumor evolution from digital histology using AI

Abstract PR005: Deep learning-based multimodal integration of histology and genomics improves cancer origin prediction

Abstract B082: Early risk stratification of ER+/HER2– breast cancer patients using digital pathology and multi-task, weakly-supervised deep learning

Abstract LB243: Deep learning-based molecular characterization of lung cancers from never smokers using hematoxylin and eosin-stained whole slide images

Abstract 6189: Deep-learning model trained on multiplex immunofluorescence-stained tissue samples predicts the survival of patients with non-small cell lung cancer better than PD-L1 TPS alone

Abstract 188: Deep learning enables label-free profiling of the tumor microenvironment and enrichment of rare cancer cells

Abstract 3532: Transforming genomic data into images for enhanced deep learning in precision oncology

Abstract 7393: Tumor model to tumor treatment: Applying deep learning approaches to map multimodal data from cancer model systems to patients